Abstract:Pancreatic ductal adenocarcinoma (PDAC) has poor survival outcomes. The main reasons include late presentation, resulting in only 20% of patients being eligible for surgery, and poor response to chemotherapy, secondary to the challenging tumour biology (1,2). For patients undergoing surgery, the local anatomy and invasiveness of PDAC results in high operative risks, with morbidity and mortality estimated at 50-70% and 2-8%, respectively (3,4). The incidence of PDAC is rising, making it the fourth leading cause of death in the United States (5). It is imperative to prioritise PDAC research. Technological advances may improve patient outcomes through early detection and optimisation of treatments. The editorial highlights the latest technological advances in PDAC and identifies areas for research.Technological breakthroughs enabling early detection of PDAC were described in a review on liquid biopsy (6). This sampling method uses biomarkers such as circulating tumour DNA (ctDNA) and extracellular vesicles (EVs). Liquid biopsy is exciting due to its non-invasive, real-time and repeatable properties. Recent advances in methylation analysis, detecting epigenetic reprogramming in early tumorigenesis, have improved the detection of PDAC using ctDNA. A meta-analysis performed in 2019 showed sensitivity and specificity rates of 70% and 86% respectively. Another biomarker showing promise are EVs, with one study showing high sensitivity and specificity rates of 99% and 82% respectively. The current accuracy of liquid biopsy across all methods for PDAC was investigated in a meta-analysis (7). They concluded that liquid biopsy using biomarkers such as ctDNA was less accurate than CA19-9 for PDAC detection. However, ctDNA was associated with worse survival, making it a useful prognostication tool. Further research utilising multiple biomarkers may increase the accuracy in PDAC detection.Advances in neoadjuvant chemotherapy regimens are enabling surgical treatment for patients with locally advanced PDAC. Zhang et al. documented the case of a patient with a locally advanced PDAC (8). Following six cycles of GEM-NabP chemotherapy the patient underwent surgery, with histology confirming near-complete response. Successes such as this are often attributed to favourable biology, but standardisation of neoadjuvant regimens may improve overall outcomes. Further improvements in neoadjuvant treatments are seen in combination with immunotherapy. Lu and colleagues published a case report of combined neoadjuvant treatment using a programmed cell death protein-1 inhibitor and chemoradiotherapy (9). Following neoadjuvant treatment for a locally advanced PDAC, the patient underwent a pylorus-preserving pancreaticoduodenectomy (PPPD) with histology showing a pathologic complete response.Further data is also showing the benefit of established adjuvant chemotherapy regimens. A retrospective cohort study by Choi and colleagues analysed outcomes for patients who received adjuvant chemotherapy for locally advanced PDAC (10). They showed that 5-fluorouracil-based regimens resulted in favourable survival. New advances have also been made in the delivery of chemotherapy. Cao et al. performed a meta-analysis of regional intra-arterial chemotherapy (RIAC) compared with systemic treatment (11). RIAC has been developed recently and trialled in PDAC due to its ability to deliver high concentrations locally, while maintaining low systemic drug levels. Their analysis concluded that patients who received RIAC had a higher rate of partial remission and fewer complications. The studies highlighted show progress within chemotherapy and immunotherapy. There is an urgent need for standardisation of regimens, combination therapy and drug delivery.Technological advances in radiotherapy (RT) for PDAC were highlighted in a review article by Malla et al (12). Despite the ability to convert borderline resectable cases to surgical resection, up to a third of patients can die during RT from disease progression. Advances in Stereotactic Body Radiation Therapy (SBRT) and hypofractionation enable the delivery of biologically effective doses with reduced toxicity to surrounding tissues. Specifically, innovation in magnetic resonance-guided on-table adaptive RT is enabling this. A recent phase two trial demonstrated reduced incidence of acute grade 3+ gastrointestinal toxicity at 90 days post treatment. New trials are also being conducted on nanoparticles to enhance RT delivery. Hafnium oxide nanoparticles NBTXR3 are activated by RT to improve radiation-induced abscopal effects. These technologies are likely to improve the effects of neoadjuvant RT for patients with PDAC. Healthcare professionals will have the tools to deliver highly effective doses of RT without the tissue toxicity that currently limits the treatment potential of this therapy.For patients eligible for surgery, advances in surgical technology are improving -Abstract Truncated-

Role of radiotherapy in combination with chemotherapy, targeted therapy, and immunotherapy in the management of pancreatic cancer

Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?

The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma

Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature

Pancreatic Ductal Adenocarcinoma: Current and Emerging Treatments

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities

Pancreatic cancer: new approaches to drug therapy

Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature

Pancreatic Cancer: A Review of Current Treatment and Novel Therapies

Updates of Chemotherapy and Radiotherapy for Pancreatic Cancer

The evolving role of radiation in pancreatic cancer

Current Status of Immunotherapies for Treating Pancreatic Cancer

Editorial: Technological innovations and pancreatic cancer

Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions

Consensus, debate, and prospective on pancreatic cancer treatments

Advancing Immunotherapy in Pancreatic Cancer

Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Advances in Systemic Therapy in Pancreatic Cancer

Stereotactic radiotherapy and the potential role of magnetic resonance-guided adaptive techniques for pancreatic cancer